Bank of America started coverage on shares of Sangamo Therapeutics (NASDAQ:SGMO) in a report published on Wednesday, June 20th, MarketBeat Ratings reports. The firm issued a buy rating and a $24.00 price objective on the biopharmaceutical company’s stock.
Other research analysts have also issued reports about the stock. Wedbush reiterated a hold rating and set a $8.00 price target on shares of Sangamo Therapeutics in a research note on Tuesday, March 13th. Barclays restated a buy rating and set a $30.00 target price on shares of Sangamo Therapeutics in a research report on Sunday, February 25th. Jefferies Financial Group reaffirmed a buy rating on shares of Sangamo Therapeutics in a report on Friday, February 23rd. BidaskClub downgraded shares of Sangamo Therapeutics from a strong-buy rating to a buy rating in a research note on Saturday, March 17th. Finally, ValuEngine raised shares of Sangamo Therapeutics from a hold rating to a buy rating in a research note on Monday, April 2nd. One analyst has rated the stock with a sell rating, two have assigned a hold rating and six have issued a buy rating to the company. The stock presently has a consensus rating of Buy and an average price target of $22.00.
Sangamo Therapeutics opened at $14.20 on Wednesday, Marketbeat Ratings reports. The company has a market capitalization of $1.41 billion, a P/E ratio of -20.29 and a beta of 2.89. The company has a debt-to-equity ratio of 0.14, a current ratio of 4.78 and a quick ratio of 4.78. Sangamo Therapeutics has a fifty-two week low of $8.00 and a fifty-two week high of $27.50.
Sangamo Therapeutics (NASDAQ:SGMO) last released its quarterly earnings data on Tuesday, May 8th. The biopharmaceutical company reported ($0.23) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.29 by ($0.52). Sangamo Therapeutics had a negative return on equity of 30.96% and a negative net margin of 126.96%. The firm had revenue of $12.60 million for the quarter, compared to analysts’ expectations of $53.09 million. During the same period last year, the firm posted ($0.23) earnings per share. Sangamo Therapeutics’s revenue for the quarter was up 270.6% on a year-over-year basis. sell-side analysts expect that Sangamo Therapeutics will post -0.65 EPS for the current year.
In related news, VP Curt A. Herberts III sold 8,163 shares of the firm’s stock in a transaction that occurred on Friday, April 13th. The shares were sold at an average price of $20.00, for a total transaction of $163,260.00. Following the completion of the sale, the vice president now directly owns 22,788 shares in the company, valued at $455,760. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO Kathy Yi sold 5,000 shares of Sangamo Therapeutics stock in a transaction that occurred on Tuesday, May 15th. The shares were sold at an average price of $15.38, for a total transaction of $76,900.00. Following the completion of the sale, the chief financial officer now owns 12,250 shares of the company’s stock, valued at $188,405. The disclosure for this sale can be found here. In the last three months, insiders have sold 47,656 shares of company stock worth $844,303. 1.20% of the stock is owned by corporate insiders.
Large investors have recently modified their holdings of the company. First Mercantile Trust Co. boosted its stake in shares of Sangamo Therapeutics by 93.7% in the 1st quarter. First Mercantile Trust Co. now owns 7,666 shares of the biopharmaceutical company’s stock valued at $146,000 after purchasing an additional 3,708 shares in the last quarter. Princeton Capital Management LLC acquired a new position in Sangamo Therapeutics during the 1st quarter valued at about $149,000. Fred Alger Management Inc. acquired a new position in Sangamo Therapeutics during the 4th quarter valued at about $148,000. Wealthcare Advisory Partners LLC acquired a new position in Sangamo Therapeutics during the 1st quarter valued at about $190,000. Finally, Xact Kapitalforvaltning AB acquired a new position in Sangamo Therapeutics during the 4th quarter valued at about $175,000. Institutional investors own 56.13% of the company’s stock.
Sangamo Therapeutics Company Profile
Sangamo Therapeutics, Inc focuses on translating ground-breaking science into genomic therapies that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company's zinc finger DNA-binding protein (ZFP) technology enables specific genome editing and gene regulation.
Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.